MX2019002190A - Uso de pridopidina para tratar distonías. - Google Patents

Uso de pridopidina para tratar distonías.

Info

Publication number
MX2019002190A
MX2019002190A MX2019002190A MX2019002190A MX2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A MX 2019002190 A MX2019002190 A MX 2019002190A
Authority
MX
Mexico
Prior art keywords
treating
pridopidine
dystonias
subject
dystonia
Prior art date
Application number
MX2019002190A
Other languages
English (en)
Inventor
Hayden Michael
Papapetropoulos Spyridon
Matti Savola Juha-
Eyal Eli
Borowsky Beth
D Grachev Igor
Forrest Gordon Mark
Original Assignee
Prilenia Therapeutics Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Therapeutics Dev Ltd filed Critical Prilenia Therapeutics Dev Ltd
Publication of MX2019002190A publication Critical patent/MX2019002190A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención proporciona un método para tratar a un sujeto afectado por una distonía, que comprende administrar periódicamente al sujeto una composición farmacéutica que comprende una cantidad de pridopidina efectiva para tratar al sujeto.
MX2019002190A 2016-08-24 2017-08-24 Uso de pridopidina para tratar distonías. MX2019002190A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662379175P 2016-08-24 2016-08-24
US201662395319P 2016-09-15 2016-09-15
PCT/US2017/048458 WO2018039475A1 (en) 2016-08-24 2017-08-24 Use of pridopidine for treating dystonias

Publications (1)

Publication Number Publication Date
MX2019002190A true MX2019002190A (es) 2019-09-11

Family

ID=61246309

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002190A MX2019002190A (es) 2016-08-24 2017-08-24 Uso de pridopidina para tratar distonías.

Country Status (9)

Country Link
US (2) US11826361B2 (es)
EP (1) EP3503890A4 (es)
JP (2) JP7278210B2 (es)
CN (1) CN110012661A (es)
AU (1) AU2017315781B2 (es)
BR (1) BR112019003731A2 (es)
CA (1) CA3035099C (es)
MX (1) MX2019002190A (es)
WO (1) WO2018039475A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
DK3261721T3 (da) 2015-02-25 2022-11-28 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til forbedring af hukommelse
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
MX2019002265A (es) 2016-08-24 2019-10-30 Prilenia Therapeutics Dev Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
SE0401465D0 (sv) * 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
EP2204363A1 (en) * 2004-06-08 2010-07-07 NSAB, Filial af NeuroSearch Sweden AB, Sverige New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission
DK1802573T3 (en) 2004-10-13 2016-12-19 Teva Pharmaceuticals Int Gmbh METHOD OF SYNTHESIS OF 4- (3-METHANSULPHONYLPHENYL) -1-N-PROPYL-PIPERIDINE.
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP2146961B1 (en) 2007-04-12 2014-01-29 IVAX International GmbH N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
US8562488B2 (en) * 2009-10-05 2013-10-22 The Cleveland Clinic Foundation Systems and methods for improving motor function with assisted exercise
WO2011107583A1 (en) * 2010-03-04 2011-09-09 Nsab, Filial Af Neurosearch Sweden Ab, Sverige Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders
CA2810092A1 (en) 2010-09-03 2012-03-08 IVAX International GmbH Deuterated analogs of pridopidine useful as dopaminergic stabilizers
US9006445B2 (en) 2011-09-07 2015-04-14 IVAX International GmbH Polymorphic form of pridopidine hydrochloride
US9012476B2 (en) * 2011-12-08 2015-04-21 IVAX International GmbH Hydrobromide salt of pridopidine
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CA2869145A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
US20140037850A1 (en) * 2012-08-06 2014-02-06 General Electric Company Corrosion and wear resistant organic coatings
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
US20150202302A1 (en) * 2014-01-22 2015-07-23 IVAX International GmbH Modified release formulations of pridopidine
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
DK3261721T3 (da) 2015-02-25 2022-11-28 Prilenia Neurotherapeutics Ltd Anvendelse af pridopidin til forbedring af hukommelse
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
US20170020854A1 (en) 2015-07-22 2017-01-26 Teva Pharmaceuticals International Gmbh Pridopidine base formulations and their use
EP3419622B1 (en) 2016-02-24 2024-03-06 Prilenia Neurotherapeutics Ltd. Treatment of neurodegenerative eye disease using pridopidine
MX2019002265A (es) 2016-08-24 2019-10-30 Prilenia Therapeutics Dev Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
JP2019529411A (ja) 2016-09-15 2019-10-17 プリレニア ニューロセラピューティクス リミテッド 不安症およびうつ病の治療のためのプリドピジンの使用
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
WO2018053275A1 (en) 2016-09-16 2018-03-22 Teva Pharmaceuticals International Gmbh Use of pridopidine for the treatment of familial dysautonomia
DK3570940T3 (da) 2017-01-20 2024-02-19 Prilenia Neurotherapeutics Ltd Pridopidin til anvendelse i behandling af fragilt x-syndrom
CN116370473A (zh) 2017-08-14 2023-07-04 普瑞尼亚神经治疗有限公司 用普利多匹定治疗肌萎缩性脊髓侧索硬化症的方法
AU2018329628B2 (en) 2017-09-08 2021-04-22 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias

Also Published As

Publication number Publication date
US11826361B2 (en) 2023-11-28
WO2018039475A1 (en) 2018-03-01
CA3035099C (en) 2023-01-17
JP7278210B2 (ja) 2023-05-19
WO2018039475A8 (en) 2018-10-04
JP7278327B2 (ja) 2023-05-19
CA3035099A1 (en) 2018-03-01
US20190192496A1 (en) 2019-06-27
CN110012661A (zh) 2019-07-12
BR112019003731A2 (pt) 2019-07-16
US20240075021A1 (en) 2024-03-07
EP3503890A1 (en) 2019-07-03
JP2019524897A (ja) 2019-09-05
EP3503890A4 (en) 2020-05-06
JP2021119189A (ja) 2021-08-12
AU2017315781A1 (en) 2019-04-11
AU2017315781B2 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
MX2019002190A (es) Uso de pridopidina para tratar distonías.
PH12017500621A1 (en) Triazolopyrazinones as pde1 inhibitors
PH12019501097A1 (en) Magl inhibitors
MX2017011997A (es) Carbamatos de piperacina y metodos de preparacion y uso.
GB2541571A (en) Pharmaceutical compositions
PH12019501102A1 (en) Magl inhibitors
PH12015502075A1 (en) Treatment of cataplexy
BR112016022855A2 (pt) composições e métodos para modular a expressão de pkk
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
PH12017501990A1 (en) Imidazopyrazinones as pde1 inhibitors
EA201792496A1 (ru) Способы лечения воспаления или нейропатической боли
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MX2017014456A (es) Usos terapeuticos de l-4-cloroquinurenina.
NZ740817A (en) Pcna inhibitors
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
TW201613610A (en) Use of ginsenoside M1 for treating lupus nephritis
BR112018005602A2 (pt) composição para tratar dor
PH12016501495A1 (en) Hexahydrofuropyrroles as pde1 inhibitors
MX2017017119A (es) Formulacion de alta concentracion.
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
MX2018003040A (es) Metodos para el tratamiento de formas recurrentes de esclerosis multiple.
NZ779760A (en) Pcna inhibitors